AstraZeneca Pre-Tax Income 2010-2024 | AZN

AstraZeneca annual/quarterly pre-tax income history and growth rate from 2010 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
  • AstraZeneca pre-tax income for the quarter ending June 30, 2024 was $2.397B, a 14.8% increase year-over-year.
  • AstraZeneca pre-tax income for the twelve months ending June 30, 2024 was $7.746B, a 28.01% increase year-over-year.
  • AstraZeneca annual pre-tax income for 2023 was $6.899B, a 175.85% increase from 2022.
  • AstraZeneca annual pre-tax income for 2022 was $2.501B, a 1043.77% decline from 2021.
  • AstraZeneca annual pre-tax income for 2021 was $-0.265B, a 106.77% decline from 2020.
AstraZeneca Annual Pre-Tax Income
(Millions of US $)
2023 $6,899
2022 $2,501
2021 $-265
2020 $3,916
2019 $1,548
2018 $1,993
2017 $2,227
2016 $3,552
2015 $3,069
2014 $1,246
2013 $3,267
2012 $7,646
2011 $12,283
2010 $10,977
2009 $10,807
AstraZeneca Quarterly Pre-Tax Income
(Millions of US $)
2024-06-30 $2,397
2024-03-31 $2,800
2023-12-31 $897
2023-09-30 $1,652
2023-06-30 $2,088
2023-03-31 $2,262
2022-12-31 $779
2022-09-30 $922
2022-06-30 $247
2022-03-31 $553
2021-12-31 $-636
2021-09-30 $-2,001
2021-06-30 $764
2021-03-31 $1,608
2020-12-31 $1,167
2020-09-30 $853
2020-06-30 $961
2020-03-31 $935
2019-12-31 $240
2019-09-30 $409
2019-06-30 $141
2019-03-31 $758
2018-12-31 $730
2018-09-30 $477
2018-06-30 $412
2018-03-31 $374
2017-12-31 $407
2017-09-30 $746
2017-06-30 $492
2017-03-31 $582
2016-12-31 $2,183
2016-09-30 $676
2016-06-30 $-30
2016-03-31 $723
2015-12-31 $802
2015-09-30 $931
2015-06-30 $658
2015-03-31 $678
2014-12-31 $-580
2014-09-30 $322
2014-06-30 $866
2014-03-31 $638
2013-12-31 $-715
2013-09-30 $1,592
2013-06-30 $1,086
2013-03-31 $1,304
2012-12-31 $1,836
2012-09-30 $2,030
2012-06-30 $1,745
2012-03-31 $2,035
2011-12-31 $1,968
2011-09-30 $4,169
2011-06-30 $2,858
2011-03-31 $3,288
2010-12-31 $2,283
2010-09-30 $2,258
2010-06-30 $2,917
2010-03-31 $3,519
2009-12-31 $2,164
2009-09-30 $3,032
2009-06-30 $2,608
2009-03-31 $3,003
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $199.957B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51